- POSITIVE
Quarterly Revenue Cooper Companies, Inc. Jan-2025 Quarterly Revenue is $965 Million which is growth of 3.6% YoY.
- POSITIVE
Quarterly Net Profit Cooper Companies, Inc. Jan-2025 Quarterly Net Profit is $104 Million which is growth of 28.4% YoY.
3.7M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Cooper Companies, Inc. is on 02 Apr 2025 for the purpose of The Cooper Companies Inc Annual General Meeting for 2025
See details
Cooper Companies, Inc. Key Metrics
Default
All financials are in USD Million and price data in USD
VIEW MORE
High Financial Strength
Mid Valuation
Technically Bearish
Falling Comet
These stocks are the ones with good quality and mid-range financial aspects. However, their weak technical aspect reduces the investor's interest.
View Similar
Embed DVM
Cooper Companies, Inc. Stock Price Analysis
Day Price Range | 81.7 (LTP) 78.782.8 LowHigh |
Week Price Range | 81.7 (LTP) 78.782.8 LowHigh |
Month Price Range | 81.7 (LTP) 7792.8 LowHigh |
52 Week Price Range | 81.7 (LTP) 77112.4 LowHigh |
Cooper Companies, Inc. Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Inline
Cooper Companies, Inc.'s Revenue was higher than average estimate 1 time in past 2 years
EPS forecast
Current EPS
Avg. Estimate
Hit
EPS is expected to grow by 46.4% in FY25
Consensus Recommendation
19 ANALYST Recommendations
BUY
The consensus recommendation from 19 analysts for Cooper Companies, Inc. is BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Forecaster
Competitors/Peers
Quarterly Results
Annual Results
Balance Sheet
Financial Ratios
Cash Flow
Cooper Companies, Inc. - Quarterly Results
Cooper Companies, Inc. quarterly, revenue, profit, P&L - 13 Quarters history
Nested row level
Base Level
Reported Types
Originally Reported
Column Order
New to Old
Cell Coloring
YoY
Nested row level
Base Level
Export
* All financials are is in USD Million and price data in USD
Indicator | Graph | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | Jul '23 | Apr '23 | Jan '23 | Oct '22 | Jul '22 | Apr '22 | Jan '22 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Rev. | 964.7 | 1,018.4 | 1,002.8 | 942.6 | 931.6 | 927.1 | 930.2 | 877.4 | 858.5 | 848.1 | 843.4 | 829.8 | 787.2 | |
Cost Of Rev. | 304.5 | 340.7 | 339.8 | 311.4 | 307.8 | 320.6 | 320.2 | 294.5 | 300 | 311.5 | 291.3 | 297.3 | 268.8 | |
Gross Profit | 660.2 | 677.7 | 663 | 631.2 | 623.8 | 606.5 | 610 | 582.9 | 558.5 | 536.6 | 552.1 | 532.5 | 518.4 | |
478.2 | 479.3 | 470.5 | 469.5 | 470.7 | 470.8 | 458.4 | 486.6 | 409 | 433.1 | 411.5 | 399.8 | 387.6 | ||
Operating Profit | 182 | 198.4 | 192.5 | 161.7 | 153.1 | 135.7 | 151.6 | 96.3 | 149.5 | 103.5 | 140.6 | 132.7 | 130.8 | |
-26 | -27 | -28.5 | -28.9 | -29.9 | -26.3 | -26.8 | -26.1 | -26.1 | -22.8 | -17.1 | -10.8 | -6.6 | ||
Profit Before Tax | 153.3 | 168.6 | 163.7 | 130 | 120 | 106.4 | 118.8 | 65.6 | 122.1 | 72.4 | 117.3 | 163.7 | 121.9 | |
Tax | 49 | 51.1 | 59 | 41.1 | 38.8 | 21.9 | 33.5 | 25.8 | 37.5 | 6.8 | 18.9 | 37.1 | 26.6 | |
104.3 | 117.5 | 104.7 | 88.9 | 81.2 | 84.5 | 85.3 | 39.8 | 84.6 | 65.6 | 98.4 | 126.6 | 95.3 | ||
Diluted NI Avail to Com Stockholders Ann. | 104.3 | 117.5 | 104.7 | 88.9 | 81.2 | 84.5 | 85.3 | 39.8 | 84.6 | 65.6 | 98.4 | 126.6 | 95.3 | |
Basic EPS | 0.5 | 0.6 | 0.5 | 0.5 | - | 0.4 | 0.4 | 0.2 | 0.4 | 0.3 | 0.5 | 0.6 | 0.5 | |
Diluted EPS After ExtraOrdinary | 0.5 | 0.6 | 0.5 | 0.5 | - | 0.4 | 0.4 | 0.2 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | |
Number Of Shares End | 199.7 | 199.2 | 199.1 | 198.9 | - | 198 | 198 | 198 | 197.6 | 197.2 | 197.2 | 197.2 | 197.6 | |
Net Income Continuing Discontinued Operations | 104.3 | 117.5 | 104.7 | 88.9 | 81.2 | 84.5 | 85.3 | 39.8 | 84.6 | 65.6 | 98.4 | 126.6 | 95.3 | |
Normalized Income | 106.3 | 118.9 | 104.4 | 90.6 | 82 | 85.2 | 88.4 | 41.5 | 83.9 | 72.4 | 102.5 | 94.6 | 97.9 | |
Interest Income | - | - | - | - | - | - | - | - | - | - | - | - | - | |
Interest | 26 | 27 | 28.5 | 28.9 | 29.9 | 26.3 | 26.8 | 26.1 | 26.1 | 22.8 | 17.1 | 10.8 | 6.6 | |
Net Interest Income | -26 | -27 | -28.5 | -28.9 | -29.9 | -26.3 | -26.8 | -26.1 | -26.1 | -22.8 | -17.1 | -10.8 | -6.6 | |
EBIT | 179.3 | 195.6 | 192.2 | 158.9 | 149.9 | 132.7 | 145.6 | 91.7 | 148.2 | 95.2 | 134.4 | 174.5 | 128.5 | |
EBITDA | 270.3 | 286.6 | 281.2 | 257.2 | 246.7 | 225.4 | 240.1 | 182.5 | 237.9 | 184.2 | 216.1 | 267.9 | 210.5 | |
Reconciled Cost Of Rev. | 263.1 | 299.9 | 301.2 | 263.4 | 261.3 | 274.4 | 272.4 | 250.2 | 256.8 | 268.5 | 249.7 | 255 | 229.1 | |
Reconciled Depr. | 91 | 91 | 89 | 98.3 | 96.8 | 92.7 | 94.5 | 90.8 | 89.7 | 89 | 81.7 | 93.4 | 82 | |
Profit From Continuing Operations | 104.3 | 117.5 | 104.7 | 88.9 | 81.2 | 84.5 | 85.3 | 39.8 | 84.6 | 65.6 | 98.4 | 126.5 | 95.3 | |
Normalized EBITDA | 273.3 | 288.6 | 280.7 | 259.7 | 247.9 | 226.3 | 244.4 | 185.3 | 236.9 | 191.7 | 221 | 226.5 | 213.8 |
*All financials are in $ Million
Add metric to table
Search...
Cooper Companies, Inc. Stock Analysis
Cooper Companies, Inc. stock analysis with key metrics, changes, and trends.
Cooper Companies, Inc. Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $3,895.4 M | 8.41% | positive |
| |
Annual Net Profit | $392.3 M | 33.34% | positive |
| |
Price to Earning Ratio | 39.33 | - | negative |
| |
Stock Price | $81.71 | -18.63% | negative |
| |
Quarterly Revenue | $964.7 M | 3.55% | positive |
| |
Quarterly Net profit | $104.3 M | 28.45% | positive |
| |
Debt to Equity Ratio | 0.32 | - | positive |
| |
Return on Equity(ROE) | 5.02 % | 5.02% | negative |
| |
Mutual Fund Holding | 82.36 % | 1.21% | positive |
| |
Promoter Share Holding | 1.43 % | 0.24% | positive |
| |
Interest Coverage Ratio | 6.09 | - | positive |
| |
Institutional Holding | 99.13 % | -0.14% | negative |
|
Loading data..
Cooper Companies, Inc. - Company Profile
What does Cooper Companies, Inc. do?

CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.
Cooper Companies, Inc. Management structure
All Gross Remunerations are in USD